Who are Fluticasone Furoate/Umeclidinium/Vilanterol (FUV)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): FF/UMEC/VI, FF/UMEC/VI (100/62.5/25) mcg, FF/UMEC/VI (200/62.5/25) mcg, FF/UMEC/VI (200/31.25/25) mcg.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fluticasone-furoate-umeclidinium-vilanterol-fuv.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Fluticasone Furoate/Umeclidinium/Vilanterol (FUV) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fluticasone Furoate/Umeclidinium/Vilanterol (FUV) (Fluticasone Furoate/Umeclidinium/Vilanterol (FUV)) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination inhaler (ICS/LAMA/LABA). Area: Respiratory.

marketed Combination inhaler (ICS/LAMA/LABA) Airway inflammation and bronchoconstriction Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Fluticasone Furoate/Umeclidinium/Vilanterol (FUV) (Fluticasone Furoate/Umeclidinium/Vilanterol (FUV)) — Thammasat University. FUV is a triple-combination inhaler that integrates a corticosteroid (fluticasone furoate), a long-acting muscarinic antagonist (umeclidinium), and a long-acting beta2-adrenergic agonist (vilanterol) to provide synergistic bronchodilation and anti-inflammatory effects.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Fluticasone Furoate/Umeclidinium/Vilanterol (FUV) TARGET	Fluticasone Furoate/Umeclidinium/Vilanterol (FUV)	Thammasat University	marketed	Combination inhaler (ICS/LAMA/LABA)	Airway inflammation and bronchoconstriction
FF/UMEC/VI	FF/UMEC/VI	Dr. Grace Parraga	marketed	Triple combination inhaler (ICS/LAMA/LABA)	Beta-2 adrenergic receptor, muscarinic M3 receptor, glucocorticoid receptor
FF/UMEC/VI (100/62.5/25) mcg	FF/UMEC/VI (100/62.5/25) mcg	GlaxoSmithKline	phase 3	Triple combination inhaler (ICS/LAMA/LABA)	Beta-2 adrenergic receptor, muscarinic M3 receptor, glucocorticoid receptor
FF/UMEC/VI (200/62.5/25) mcg	FF/UMEC/VI (200/62.5/25) mcg	GlaxoSmithKline	phase 3	Triple combination inhaler (ICS/LAMA/LABA)	M3 muscarinic receptor, beta-2 adrenergic receptor, glucocorticoid receptor
FF/UMEC/VI (200/31.25/25) mcg	FF/UMEC/VI (200/31.25/25) mcg	GlaxoSmithKline	phase 3	Triple combination inhaler (ICS/LAMA/LABA)	Glucocorticoid receptor, M3 muscarinic receptor, beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-07-15 — Fluticasone Furoate/Umeclidinium/Vilanterol (FUV) · 8347879 · Formulation · US
2028-10-15 — Fluticasone Furoate/Umeclidinium/Vilanterol (FUV) · 8147461 · Formulation · US

Sponsor landscape (Combination inhaler (ICS/LAMA/LABA) class)

Thammasat University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fluticasone Furoate/Umeclidinium/Vilanterol (FUV) — Competitive Intelligence Brief. https://druglandscape.com/ci/fluticasone-furoate-umeclidinium-vilanterol-fuv. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab